Clinical trials should be designed to ease travel and financial burdens by using local care, telehealth and remote tools, Kimberly Demirhan explained.

New clinical trials are advancing treatments for cutaneous T-cell lymphoma, advanced solid tumors, pediatric sarcomas and ALK-positive lung cancer.

New clinical trials are advancing in hard-to-treat cancers, offering targeted and less toxic options for patients with limited treatment paths.

Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing safety/activity with novel therapies.

The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma.

A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment in the phase 1 PMB-102 trial.

The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.

The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 DENALI clinical trial.

A patient with heavily pretreated relapsed/refractory diffuse large B-cell lymphoma achieved complete remission following novel in vivo CD19 CAR-T therapy.

A phase 1 trial has initiated and is investigating treatment with ziftomenib plus Gleevec in advanced GIST following progression on Gleevec.

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus immune checkpoint inhibitors.

Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.

A phase 1 clinical trial is open for enrollment to patients with high-grade neuroendocrine tumors.

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ovarian cancer has been launched.

The FDA has approved an application to initiate a pilot study with Alpha DaRT for patients with recurrent glioblastoma, a form of brain cancer.

Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to COMPANION-002 study results.

A patient with HPV-positive head and neck squamous cell carcinoma was dosed in a phase 1 clinical trial evaluating APR-1051.

The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with melanoma.

A progress report for a phase 1 trial of CLD-101 in recurrent glioma shows safety and feasibility at multiple intracerebral doses.

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced non-small cell lung cancer.

The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory agencies.

The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.

The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with myelodysplastic syndrome.

The first participant has been dosed on the phase 2 CONVERGE study evaluating NBTXR3 in stage III, unresectable non–small cell lung cancer.

The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in metastatic breast cancer.

A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus endocrine therapy.